Eur Rev Med Pharmacol Sci 2019; 23 (14): 6119-6130

DOI: 10.26355/eurrev_201907_18425

MiR-511-5p functions as a tumor suppressor and a predictive of prognosis in colorectal cancer by directly targeting GPR116

C. Wang, H.-Q. Fan, Y.-W. Zhang

Department of Gastroenterology, Department of Rehabilitative Medicine; Affiliated Hospital of Jining Medical University, Jining, Shandong, China. xueshan3636@163.com


OBJECTIVE: Previous studies have revealed that miR-511-5p was abnormally expressed in several cancers. In this study, we aimed to develop a study on the expression patterns, clinical value, and functional roles of miR-511-5p in colorectal cancer (CRC).

PATIENTS AND METHODS: MiR-511-5p and GPR116 were analyzed in CRC cell lines and tumor specimens by Real-time PCR. The clinical correlations between miR-511-5p expression and the clinicopathologic factors and prognosis were analyzed. The potential influences of miR-511-5p expression on CRC cell growth, apoptosis, and invasion abilities were analyzed by MTT, clonogenic assay, flow cytometry and transwell assay, respectively. Luciferase assays, qRT-PCR and Western blotting were carried out for the discovery of the target gene of miR-511-5p.

RESULTS: MiR-511-5p was dramatically decreased in CRC samples and cells. Reduced miR-511-5p expressions were negatively correlated with histology/differentiation, invasion and TNM stage. Moreover, miR-511-5p was capable of being an independent prognostic predictor for CRC patients. It was also observed that overexpression of miR-511-5p depressed CRC cell growth and invasive abilities, and stimulated apoptosis. Mechanistically, we showed that miR-511-5p targeted the 3’-UTR of GPR116 and GPR116 reversed partial function of miR-511-5p in vitro.

CONCLUSIONS: MiR-511-5p may be used as a novel prognostic biomarker and functions as a novel anti-oncogene in CRC and the anti-oncogenic activity may involve its inhibition of the target gene GPR116.

Free PDF Download

To cite this article

C. Wang, H.-Q. Fan, Y.-W. Zhang
MiR-511-5p functions as a tumor suppressor and a predictive of prognosis in colorectal cancer by directly targeting GPR116

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 14
Pages: 6119-6130
DOI: 10.26355/eurrev_201907_18425